Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Visceral leishmaniases].

Eric Rosenthal1, Pierre Marty

  • 1Service de médecine interne, hôpital de l'Archet, CHU de Nice, 06202 Nice Cedex. rosenthal.e@chu-nice.fr

La Revue Du Praticien
|March 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Imported Schistosomiasis among unaccompanied minor migrants in Nice (France)].

Medecine tropicale et sante internationale·2026
Same author

A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.

Nature immunology·2026
Same author

Leadless atrial pacemaker implantation after covered stent correction for superior sinus venous defect-A case report.

HeartRhythm case reports·2026
Same author

Transcatheter Repair of Sinus Venosus Defect Using a 12-zig Covered Cheatham-Platinum Stent in Large Superior Vena Cava-Right Atrium Junctions: Early Multicenter Experience.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

p16<sup>High</sup> immune cells control disease tolerance as a defense and health span-extending strategy.

Immunity·2026
Same author

International Experience of Transcatheter Sinus Venosus Defect Closure in Children and Adolescents.

Pediatric cardiology·2026

Visceral leishmaniasis (VL) treatment varies by region due to drug resistance and co-infections like HIV. Lipid formulations of amphotericin B are preferred in the Mediterranean, while antimonials are key elsewhere.

Area of Science:

  • Tropical medicine
  • Infectious diseases
  • Public health

Context:

  • Visceral leishmaniasis (VL) presents diverse clinical and therapeutic challenges globally.
  • Epidemics are spreading in India and Sudan, with sporadic cases in the Mediterranean basin.
  • Human immunodeficiency virus (HIV) co-infection with VL is emerging in Europe and may spread to other endemic regions.

Purpose:

  • To outline the geographically variable clinical, therapeutic, and public health aspects of visceral leishmaniasis.
  • To highlight the implications of drug resistance and emerging co-infections for VL management.

Summary:

  • Treatment strategies for VL differ significantly based on geographic location and local drug resistance patterns.
  • Lipid formulations of amphotericin B are recommended as first-line treatment in the Mediterranean basin.

Related Experiment Videos

  • Pentavalent antimonials are the primary treatment in non-resistant areas; alternatives include conventional amphotericin B or miltefosine in resistant zones.

    • Impact:

    • Informing tailored treatment guidelines for visceral leishmaniasis.
    • Guiding public health strategies to address VL and its co-infections.
    • Improving patient outcomes through appropriate drug selection based on geographic context and resistance profiles.